Qelbree vs. Strattera: Comparing Two Non-Stimulant ADHD Medications
Author:
Blossom Editorial
Qelbree (viloxazine) and Strattera (atomoxetine) are two non-stimulant medications approved by the FDA specifically to treat attention-deficit/hyperactivity disorder (ADHD) in both children and adults.
Both primarily work by increasing norepinephrine signaling rather than directly targeting dopamine pathways; both are taken every day rather than as needed, and neither is a controlled substance.
The differences that matter most in practice come down to how they are dosed, how quickly they tend to work, how they interact with other medications, and what they cost.
If a stimulant has not worked well for you, caused unbearable side effects, or is not a good fit for other reasons, these two medications are usually what your provider may consider next.
This guide walks through how they compare across approval history, dosing, effectiveness, side effects, and the practical factors that often decide which one a prescriber might recommend for you.
Key Takeaways
Both are non-stimulants, but they are not interchangeable: Strattera has been available since 2002 and comes in a low-cost generic. Qelbree was approved in 2021 for children and 2022 for adults, and is still brand-only. Both carry a boxed warning about suicidal thoughts and behavior.
Dosing and timing work differently: Strattera is dosed by body weight in most children and can be split into two daily doses. Qelbree is a once-daily capsule with fixed dose steps. Research suggests Qelbree may show early symptom improvement somewhat sooner, though both are typically given a full trial before judging results.
Drug interactions often decide the choice: Strattera is processed mainly by the CYP2D6 enzyme, and Qelbree strongly blocks the CYP1A2 enzyme. If you take other medications, that difference can matter more than any small gap in effectiveness, so bring a full medication list to your appointment.
What Are Qelbree and Strattera?
Both medications belong to a small group of ADHD treatments in the non-stimulant category. Understanding how each one works helps explain why they are dosed and prescribed so differently.
Strattera (Atomoxetine)
Strattera (Atomoxetine) was approved in 2002 and was the first non-stimulant medication cleared by the FDA for ADHD. It is a selective norepinephrine reuptake inhibitor, which means it blocks the norepinephrine transporter (NET), the protein that normally carries norepinephrine back into nerve cells (neurons).
As a result, more norepinephrine stays available in the spaces between neurons in the brain, including in the prefrontal cortex, the region involved in attention, planning, working memory, and impulse control.
Strattera also indirectly increases dopamine in certain parts of the brain by inhibiting dopamine reabsorption in the neurons. Since the NET protein is also responsible for dopamine transport in areas of the brain such as the prefrontal cortex, blocking the protein also results in an increase in dopamine levels in the brain. This is also thought to contribute to its therapeutic effects for ADHD.
Strattera is approved for ADHD in children six years of age and older, adolescents, and adults. It is not a controlled substance, and it is widely available as a generic, which makes it one of the more affordable ADHD medications on the market. It is taken as a capsule that should be swallowed whole rather than opened.
Qelbree (Viloxazine Extended-Release)
Qelbree (Viloxazine) has an unusual history. It was sold in Europe as an antidepressant starting in the early 1970s, then withdrawn from the market in 2002 for commercial reasons. Two decades later, it was reformulated as an extended-release capsule and approved for ADHD in the United States in April 2021 for children and adolescents ages 6 to 17, with approval for adults following in 2022.
Similar to Strattera, Qelbree also increases norepinephrine levels by blocking norepinephrine reuptake, but it goes further than that. It also acts on certain serotonin receptors, behaving as a partial agonist at the 5-HT2C receptor and an antagonist at the 5-HT2B receptor. Researchers believe this added serotonin activity may contribute to its clinical effects, though the FDA notes that its exact mechanism of action in ADHD remains unknown.
In addition to its effect on norepinephrine and serotonin, Qelbree also moderately increases dopamine levels in the prefrontal cortex and amygdala.
Qelbree is taken once daily. The capsule can be opened, and the contents sprinkled onto applesauce, which is a meaningful advantage for children and anyone who has trouble swallowing pills. It is not a controlled substance and is currently available only as a brand-name product.
How Do Qelbree and Strattera Compare on Dosing?
This is one of the clearest practical differences between the two, and it often shapes how the first few months of treatment feel.
Strattera Dosing
For children and adolescents weighing up to 70 kg, Strattera is dosed by body weight. Treatment usually starts around 0.5 mg per kilogram per day, then increases after a minimum of three days to a target of roughly 1.2 mg per kilogram per day. The maximum daily dose in this group is the lower of 1.4 mg per kilogram or 100 mg.
For adults and children over 70 kg, the usual starting dose is 40 mg daily, increased after at least three days to a target of 80 mg daily. If symptoms have not improved enough after several weeks, the dose may be raised to a maximum of 100 mg daily. Strattera can be taken as a single morning dose or split into two equal doses, which some people find helps with tolerability.
Qelbree Dosing
Qelbree uses fixed dose steps rather than weight-based calculations. Children ages 6 to 11 typically start at 100 mg once daily, with weekly increases of 100 mg as needed, up to a maximum of 400 mg.
Adolescents ages 12 to 17 usually start at 200 mg once daily, with a maximum of 400 mg, increased after one week. Adults typically start at 200 mg once daily, with weekly increases of 200 mg up to a maximum of 600 mg.
The once-daily structure for Qelbree simplifies dosing, although it offers fewer intermediate dose adjustments than weight-based dosing for Strattera.
Which Non-Stimulant ADHD Medication Works Better?
Unfortunately, there are no large head-to-head trials directly comparing Qelbree and Strattera, which means any comparison relies on indirect evidence. That is an important limitation to keep in mind, because indirect comparisons across separate studies with different participants can be misleading.
What the research does show is that both medications produce a real but moderate improvement in ADHD symptoms compared with placebo. A systematic review and meta-analysis from 2026 of viloxazine (Qelbree) trials found a statistically significant reduction in ADHD symptom severity in adolescents, with a pooled effect size that the authors described as similar to what has been reported for other non-stimulants including atomoxetine, and notably smaller than the effect sizes seen with stimulant medications.
Separate meta-analyses of viloxazine (Qelbree) trials have found that both the 200 mg and 400 mg doses outperformed placebo on standard ADHD rating scales, with response rates that were broadly similar between the two doses.
A systematic review and network meta-analysis published in the Lancet Psychiatry, including 113 trials, concluded that atomoxetine (Strattera) and stimulant ADHD medications were the only treatments with strong evidence of reducing core ADHD symptoms in adults over 12 weeks.
Other analyses in adult ADHD have suggested viloxazine (Qelbree) may hold a modest efficacy edge over atomoxetine (Strattera). Still, these findings come from indirect comparisons rather than direct trials, and researchers consistently note the results are preliminary.
The practical takeaway is that neither medication is clearly and reliably stronger than the other. Individual response varies far more than the average difference between the two drugs, which is why a prescriber will often try one, evaluate honestly, and switch if it is not working.
How Long Does Each Medication Take to Work?
Neither of these medications works the way a stimulant does. Stimulants can produce a noticeable effect within an hour. Non-stimulants’ effects build up over weeks, which requires patience and can be frustrating if you are expecting an immediate change.
Strattera generally requires several weeks before its full benefit becomes clear. Many prescribers ask patients to stay at a target dose for at least four to six weeks before deciding whether it is working. Some people notice early changes sooner, but a fair trial takes time.
Qelbree trials have reported symptom improvement emerging somewhat earlier, with separation from placebo appearing within the first week or two of treatment in some studies. A small study involving 50 ADHD patients (both pediatric and adult) reported that 86% of patients on viloxazine (Qelbree) reported an improvement in two weeks compared to 14% of those on atomoxetine (Strattera). However, larger direct comparison studies are needed.
Even for Qelbree, dose titration still takes weeks, and meaningful clinical improvement usually doesn’t become apparent until you have been at a stable therapeutic dose for a month or longer.
Side Effects: What to Expect From Qelbree vs. Strattera
The side effect profiles overlap considerably, which makes sense given that both medications act on norepinephrine. The differences show up in the details.
Common Side Effects of Strattera
In pediatric trials, the most frequently reported reactions included nausea, headache, vomiting, fatigue, decreased appetite, abdominal pain, and drowsiness. In adults, dry mouth, insomnia, nausea, decreased appetite, fatigue, constipation, and urinary hesitancy were among the more common complaints.
Some adults also report sexual side effects, including erectile dysfunction and reduced libido.
Strattera can produce small increases in heart rate and blood pressure, so prescribers typically check these at baseline and periodically during treatment. Rare cases of liver injury have been reported, and the label advises stopping the medication if signs of liver problems appear.
Pediatric users of Strattera are usually monitored for changes in weight and height since the medication can reduce appetite in some children.
Common Side Effects of Qelbree
In children and adolescents, the most commonly reported reactions were sleepiness, decreased appetite, headache, fatigue, nausea, vomiting, insomnia, and irritability. In adults, insomnia, headache, dry mouth, fatigue, nausea, constipation, and decreased appetite were most frequently reported.
Somnolence is worth flagging: sleepiness is one of the more common early complaints with Qelbree, and it can affect school or work performance in the first weeks. Like Strattera, Qelbree can raise heart rate and blood pressure modestly, and monitoring is recommended.
The Boxed Warning Both Medications Share
Both Qelbree and Strattera carry a boxed warning about increased risk of suicidal thoughts and behavior in children, adolescents, and young adults. This is the FDA’s most serious warning category. The risk is highest early in treatment and after dose changes.
This does not mean the medications are unsafe. It means that anyone starting them, along with their family, should watch closely for new or worsening depression, agitation, unusual behavior changes, or thoughts of self-harm, especially in the first few months, and contact the prescriber promptly if any of these appear.
Drug Interactions: A Meaningful Difference
This is where the two medications diverge most sharply, and it is frequently the deciding factor when someone takes other prescriptions.
Strattera and CYP2D6: Atomoxetine is broken down primarily by the CYP2D6 enzyme. People who are genetically poor metabolizers of this enzyme end up with substantially higher blood levels. Medications that block CYP2D6, including paroxetine, fluoxetine, and quinidine, have the same effect, and the label advises starting at a lower dose in these situations.
Strattera and antihypertensive drugs: As Strattera can cause an increase in blood pressure, it should be used carefully with antihypertensive drugs and drugs that increase blood pressure. Increased blood pressure monitoring is recommended in such cases.
Qelbree and CYP1A2: Viloxazine is a strong inhibitor of the CYP1A2 enzyme. That means it can raise blood levels of other medications that depend on CYP1A2 to be broken down. Therefore, it is contraindicated with sensitive CYP1A2 substrates (medications metabolized by the enzyme) that have a narrow safety margin.
MAOIs are off the table for both: Neither medication should be taken with a monoamine oxidase inhibitor, or within 14 days of stopping one.
Kidney and liver function matter: Qelbree requires dose reduction in severe kidney impairment. Strattera requires dose reduction in moderate to severe liver impairment.
Cost, Access, and Practical Considerations
Strattera has been generic for years, and generic atomoxetine is inexpensive relative to most ADHD medications. Qelbree, being more recently approved, is still brand-only, so out-of-pocket cost depends heavily on insurance formulary placement and prior authorization requirements. For many people, this is an important practical difference between the two.
A few other everyday details are worth noting. Qelbree capsules can be opened and sprinkled on applesauce, and the mixture consumed within two hours.
However, the contents must not be crushed or chewed. Strattera capsules are meant to stay closed, in part because the contents are an eye irritant. Strattera offers the option of twice-daily dosing, which can smooth out side effects for some people, while Qelbree is once daily only.
It is worth remembering that stimulants remain the most effective ADHD medications on average and are considered first-line treatments, and non-stimulants are usually considered when stimulants are not tolerated, not appropriate, or not preferred. For further reading, here’s our guide on the differences between stimulant and non-stimulant ADHD medications.
Which One Might Be Right for You?
The decision is usually taken based on a handful of specific factors rather than a general ranking.
Cost and coverage: Generic atomoxetine is typically far less expensive if paying out of pocket is a concern.
Other medications: If you take an SSRI like paroxetine or fluoxetine that inhibits the liver enzyme CYP2D6 responsible for its breakdown, Strattera dosing gets more complicated. If you take a medication dependent on CYP1A2, Qelbree may be a problem. For people taking medications to lower blood pressure, Qelbree may be a better option.
Side effects: Some people who experience gastrointestinal side effects on taking Strattera may notice Qelbree to be more tolerable.
Swallowing pills: Qelbree can be sprinkled on food. Strattera cannot.
Prior experience: If you have already tried atomoxetine (Strattera) without benefit, viloxazine (Qelbree) is a reasonable next step, since the two are not identical despite the shared mechanism.
Coexisting anxiety: Both are sometimes considered when anxiety accompanies ADHD, particularly when stimulants are not well tolerated or may worsen anxiety symptoms in some individuals.
If the first medication does not produce meaningful improvement after a fair trial at a therapeutic dose, switching is a normal and clinically sound next step. It is not a failure, and it does not mean nothing will work.
If you are considering either medication, a psychiatric provider can help you weigh the options against your history and other prescriptions. Blossom connects you with board-certified psychiatric providers who can prescribe and manage ADHD medication virtually, all covered by in-network insurance, and you can get started at joinblossomhealth.com/start.
Medical Disclaimer
This article is for informational purposes only and is not a substitute for professional medical advice. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or medication. Never start, stop, or change a medication without consulting your prescriber. If you are experiencing a mental health crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988.
Sources
U.S. Food and Drug Administration. (2025, January). Qelbree (viloxazine extended-release capsules) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211964s013lbl.pdf
U.S. Food and Drug Administration. (2026, January). Strattera (atomoxetine hydrochloride) capsules prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf
Mathew BM, Pellegrini MV. Viloxazine. [Updated 2023 Aug 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK576423/
Fedder D, Patel H, Saadabadi A. Atomoxetine. [Updated 2023 Mar 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493234/
National Institute of Mental Health. (2024, December). Attention-deficit/hyperactivity disorder (ADHD). U.S. Department of Health and Human Services, National Institutes of Health. https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd
Yu, C., Garcia-Olivares, J., Candler, S., Schwabe, S., & Maletic, V. (2020). New insights into the mechanism of action of viloxazine: Serotonin and norepinephrine modulating properties. Journal of Experimental Pharmacology, 12, 285–300. https://www.tandfonline.com/doi/full/10.2147/JEP.S256586#d1e1346
Chapman, S. R., Roberti, C., Abouafech, A., & Mueller, M. (2026). Efficacy and Tolerability of Viloxazine Extended-Release for Attention-Deficit/Hyperactivity Disorder in Adolescents and Adults: A Systematic Review With Qualitative Synthesis of All Studies and Meta-Analysis of Adolescent Data. Cureus, 18(3), e105176. https://pmc.ncbi.nlm.nih.gov/articles/PMC13070516/
Singh, A., Balasundaram, M. K., & Singh, A. (2022). Viloxazine for Attention-Deficit Hyperactivity Disorder: A Systematic Review and Meta-analysis of Randomized Clinical Trials. Journal of central nervous system disease, 14, 11795735221092522. https://pmc.ncbi.nlm.nih.gov/articles/PMC9125110/
Ostinelli, E. G., Schulze, M., Zangani, C., et al. (2025). Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: A systematic review and component network meta-analysis. The Lancet Psychiatry, 12(1), 32–43. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(24)00360-2/fulltext
Yu, C. L., Kao, Y. C., Thompson, T., Stubbs, B., et al. (2024). Response Trajectories and Temporal Trends of Viloxazine Treatment for Young People With ADHD: A Meta-Analysis. JAMA network open, 7(11), e2445885. https://pmc.ncbi.nlm.nih.gov/articles/PMC11577144/
Price, M. Z., & Price, R. L. (2023). Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder. CNS drugs, 37(7), 655–660. https://pmc.ncbi.nlm.nih.gov/articles/PMC10374479
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Viloxazine. [Updated 2021 Aug 20]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK573974/
Attention-Deficit/Hyperactivity Disorder Medications for Adults: Drugs [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Nov. Available from: https://www.ncbi.nlm.nih.gov/books/NBK610422/
